Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Virtu Financial LLC trimmed its holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 21.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,276 shares of the company’s stock after selling 9,112 shares during the period. Virtu Financial LLC’s holdings in Protalix BioTherapeutics were worth $64,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new stake in Protalix BioTherapeutics in the fourth quarter worth $35,000. XTX Topco Ltd bought a new stake in shares of Protalix BioTherapeutics during the 3rd quarter worth about $36,000. Sanctuary Advisors LLC bought a new stake in shares of Protalix BioTherapeutics during the 3rd quarter worth about $38,000. Finally, PFG Investments LLC bought a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at approximately $39,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PLX shares. StockNews.com downgraded Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th. HC Wainwright raised their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Stock Performance

NYSE PLX opened at $2.56 on Tuesday. The stock has a 50-day simple moving average of $2.44 and a 200 day simple moving average of $1.83. Protalix BioTherapeutics, Inc. has a twelve month low of $0.82 and a twelve month high of $2.76. The stock has a market capitalization of $199.76 million, a PE ratio of -19.69 and a beta of 0.72.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.